Antigen Binding Domains for CD70 and GPC3 Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer therapies face challenges in effectively targeting and eliminating cancer cells, particularly those expressing CD70, GPC3, and IL13Rα2 proteins, which are often involved in tumor progression and resistance to treatment.

Innovation Solution

Development of antigen binding domains, specifically heavy chain variable domains (VH) with defined complementarity determining regions (CDR) for antibodies targeting CD70, GPC3, and IL13Rα2, integrated into chimeric antigen receptors (CARs) or chimeric fusion proteins, enabling specific binding and intracellular signaling for enhanced cancer cell targeting and elimination.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current cancer therapies are used to target cancer cells expressing CD70, GPC3, and IL13Rα2 proteins, then treatment coverage is provided, but effectiveness is reduced due to tumor progression and treatment resistance

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidtumor progression and treatment resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the structure of chimeric antigen receptors by changing parameters such as the antigen-binding domain configuration, CDR sequences, and domain architecture to create novel CAR variants with improved ability to recognize and bind to cancer cells expressing CD70, GPC3, and IL13Rα2, thereby overcoming treatment resistance

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates composite chimeric antigen receptors that integrate multiple functional domains including antigen-binding domains, transmembrane domains, and intracellular signaling domains in a unified structure, enabling simultaneous targeting of multiple cancer-associated proteins and enhanced therapeutic effectiveness

Inventive Principle:

Principle #40Composite materials

2Measurement precision

If antigen binding domains with defined CDR regions are developed for targeting specific proteins, then binding specificity is improved, but development complexity increases

Engineering Contradiction:

Improvebinding specificityVSAvoidantibody structure complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent segments the antibody structure into distinct functional domains with defined complementarity determining regions (CDR1, CDR2, CDR3) in the variable heavy chain, allowing independent optimization of each domain's binding characteristics while maintaining overall structural organization

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention develops antigen-binding domains with universal structural frameworks that can be adapted to target multiple different antigens (CD70, GPC3, IL13Rα2) by modifying only the CDR regions, thereby achieving high binding specificity without requiring complete redesign of the entire antibody structure

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250090663A1Binding domains and methods of use thereof

Publication Date: 2025.03.20 MYELOID THERAPEUTICS INC

AI summary

Compositions and methods for binding to target antigens. Compositions comprising variable heavy chain domains with binding specificity to CD70, GPC3, IL13Ralpha2 and Cadherin CDH17 antigens.